KK2845_alternative_2
Phase 1
Kyowa Kirin Co., Ltd.KK2845_alternative_2 is one of 43 therapeutic programs targeting Relapsed or Refractory. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
42
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
59 competitors in Relapsed or Refractory
#DrugCompanyPhaseTrials
1Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Copiktra
SSecuraBio
Phase 3
Fludara
SanofiPhase 2
Venclexta
AbbViePhase 2
Cytosar
TevaPhase 2
Dacogen
Sun Pharmaceutical Industries, Inc.Phase 2
Oncovin
Eli LillyPhase 2
Fludara
SanofiPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for KK2845_alternative_2. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company